Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir

Table 2

Antenatal antiretroviral exposure of infants.

Drug	Number exposed (%)
Nucleoside reverse transcriptase inhibitors
Abacavir	7 (4%)
Emtricitabine	15 (9.5%)
Lamivudine	126 (80%)
Stavudine	21 (13%)
Tenofovir	15 (9.5%)
Zidovudine	99 (63%)
Nonnucleoside reverse transcriptase inhibitors
Nevirapine	10 (6%)
Protease inhibitors
Atazanavir ± ritonavir	16 (10%)
Lopinavir + ritonavir	59 (37%)
Nelfinavir	41 (26%)
Saquinavir ± ritonavir	7 (4%)

Maternal treatment administered for ≥28 days of the 35 days immediately preceding delivery.
Thirteen of sixteen women received ritonavir-boosted atazanavir.